{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:25:03Z","timestamp":1781645103029,"version":"3.54.5"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jaci-inpractice.org","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jaip.2024.10.011","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:03:12Z","timestamp":1729123392000},"page":"213-219.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Validation of the Cholinergic Urticaria Activity Score (CholUAS)"],"prefix":"10.1016","volume":"13","author":[{"given":"Pia","family":"Schnarkowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Salameh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Grekowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothea","family":"Terhorst-Molawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4121-481X","authenticated-orcid":false,"given":"Marcus","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Altrichter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2024.10.011_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.iac.2013.09.010","article-title":"Physical urticarias and cholinergic urticaria","volume":"34","author":"Abajian","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2024.10.011_bib2","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S0190-9622(94)70267-5","article-title":"Prevalence of cholinergic urticaria in young adults","volume":"31","author":"Zuberbier","year":"1994","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2024.10.011_bib3","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/cea.13102","article-title":"Development and validation of the Cholinergic Urticaria Quality-of-Life Questionnaire (CholU-QoL)","volume":"48","author":"Ruft","year":"2018","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2024.10.011_bib4","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1016\/j.jaci.2018.01.031","article-title":"Chronic inducible urticaria: a systematic review of treatment options","volume":"141","author":"Dressler","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.10.011_bib5","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.jaci.2016.05.026","article-title":"Antihistamine updosing reduces disease activity in patients with difficult-to-treat cholinergic urticaria","volume":"138","author":"Koch","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.10.011_bib6","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jaci.2013.12.1076","article-title":"Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control","volume":"133","author":"Weller","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.10.011_bib7","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jaci.2018.08.050","article-title":"Real-life treatment of cholinergic urticaria with omalizumab","volume":"143","author":"Altrichter","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.10.011_bib8","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14010","article-title":"Omalizumab for cholinergic urticaria: 6 months prospective study and systematic review of the literature","volume":"33","author":"Ghazanfar","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaip.2024.10.011_bib9","doi-asserted-by":"crossref","first-page":"234","DOI":"10.4103\/idoj.idoj_584_21","article-title":"Cyclosporine in cholinergic itch","volume":"13","author":"Sehgal","year":"2022","journal-title":"Indian Dermatol Online J"},{"key":"10.1016\/j.jaip.2024.10.011_bib10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.7205\/MILMED.173.2.217","article-title":"Successful treatment of disabling cholinergic urticaria","volume":"173","author":"Feinberg","year":"2008","journal-title":"Mil Med"},{"key":"10.1016\/j.jaip.2024.10.011_bib11","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/1346-8138.12765","article-title":"Successful treatment of cholinergic urticaria with methantheliniumbromide","volume":"42","author":"Altrichter","year":"2015","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaip.2024.10.011_bib12","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/WOX.0b013e31825a72fc","article-title":"Evaluation of different combined regimens in the treatment of cholinergic urticaria","volume":"5","author":"Alsamarai","year":"2015","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaip.2024.10.011_bib13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jdermsci.2014.04.007","article-title":"Development of a standardized pulse-controlled ergometry test for diagnosing and investigating cholinergic urticaria","volume":"75","author":"Altrichter","year":"2014","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.jaip.2024.10.011_bib14","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.jaci.2021.12.772","article-title":"An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria","volume":"149","author":"Altrichter","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.10.011_bib15","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","article-title":"Content validity\u2014establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1\u2014eliciting concepts for a new PRO instrument","volume":"14","author":"Patrick","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.jaip.2024.10.011_bib16","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","article-title":"Content validity\u2014establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2\u2014assessing respondent understanding","volume":"14","author":"Patrick","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.jaip.2024.10.011_bib17","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2340\/00015555-1199","article-title":"Turkish version of the chronic urticaria quality of life questionnaire: cultural adaptation, assessment of reliability and validity","volume":"92","author":"Kocat\u00fcrk","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaip.2024.10.011_bib18","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/all.13271","article-title":"Comparison and interpretability of the available urticaria activity scores","volume":"73","author":"Hawro","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2024.10.011_bib19","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.jaip.2017.10.001","article-title":"The urticaria activity score\u2014validity, reliability, and responsiveness","volume":"6","author":"Hawro","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.10.011_bib20","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/all.12901","article-title":"Definition, aims, and implementation of GA(2) LEN Urticaria Centers of Reference and Excellence","volume":"71","author":"Maurer","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2024.10.011_bib21","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12874-018-0594-7","article-title":"Characterising and justifying sample size sufficiency in interview-based studies: systematic analysis of qualitative health research over a 15-year period","volume":"18","author":"Vasileiou","year":"2018","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jaip.2024.10.011_bib22","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaip.2024.10.011_bib23","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/nur.4770130405","article-title":"A\u00a0critical review of visual analogue scales in the measurement of clinical phenomena","volume":"13","author":"Wewers","year":"1990","journal-title":"Res Nurs Health"},{"key":"10.1016\/j.jaip.2024.10.011_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2021.637547","article-title":"A\u00a0review of key Likert scale development advances: 1995-2019","volume":"12","author":"Jebb","year":"2021","journal-title":"Front Psychol"},{"key":"10.1016\/j.jaip.2024.10.011_bib25","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/j.1398-9995.2011.02580.x","article-title":"Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA(2) LEN taskforce position paper","volume":"66","author":"Baiardini","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2024.10.011_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2022.867227","article-title":"Disease impact, diagnostic delay, and unmet medical needs of patients with cholinergic urticaria in German-speaking countries","volume":"3","author":"Altrichter","year":"2022","journal-title":"Front Allergy"},{"key":"10.1016\/j.jaip.2024.10.011_bib27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2340\/0001555575147149","article-title":"Efficacy of cetirizine in cholinergic urticaria","volume":"75","author":"Zuberbier","year":"1995","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaip.2024.10.011_bib28","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1159\/000246281","article-title":"Double-blind crossover study of high-dose cetirizine in cholinergic urticaria","volume":"193","author":"Zuberbier","year":"1996","journal-title":"Dermatology"},{"key":"10.1016\/j.jaip.2024.10.011_bib29","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.jaip.2018.12.025","article-title":"Efficacy and safety of omalizumab (Xolair) for cholinergic urticaria in patients unresponsive to a double dose of antihistamines: a randomized mixed double-blind and open-label placebo-controlled clinical trial","volume":"7","author":"Gastaminza","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.10.011_bib30","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1111\/all.15310","article-title":"Development of the Cold Urticaria Activity Score","volume":"77","author":"Ahsan","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2024.10.011_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12089","article-title":"Chronic urticaria patients are interested in apps to monitor their disease activity and control: a UCARE CURICT analysis","volume":"11","author":"Cherrez-Ojeda","year":"2021","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2024.10.011_bib32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5339\/qmj.2023.sqac.14","article-title":"CRUSE\u2014What the first 100 days have taught us","volume":"2023","author":"Neisinger","year":"2023","journal-title":"Qatar Med J"},{"key":"10.1016\/j.jaip.2024.10.011_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12328","article-title":"CRUSE\u00ae\u2014an innovative mobile application for patient monitoring and management in chronic spontaneous urticaria","volume":"14","author":"Neisinger","year":"2024","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2024.10.011_bib34","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13223-020-00496-0","article-title":"Refractory chronic urticaria in adults: clinical characterization and predictors of severity","volume":"16","author":"Alen","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2024.10.011_bib35","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1111\/cea.13023","article-title":"Cholinergic urticaria patients of different age groups have distinct features","volume":"47","author":"Asady","year":"2017","journal-title":"Clin Exp Allergy"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219824010651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219824010651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T06:08:18Z","timestamp":1736316498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219824010651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2213219824010651"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2024.10.011","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validation of the Cholinergic Urticaria Activity Score (CholUAS)","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2024.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}